Last update 21 Nov 2024

Reboxetine(Axsome Therapeutics, Inc.)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Reboxetine, Reboxetine (INN)
+ [1]
Mechanism
ADRA2 antagonists(Adrenergic receptors alpha-2 antagonists), NET inhibitors(Norepinephrine transporter inhibitors)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC19H23NO3
InChIKeyCBQGYUDMJHNJBX-PVIFGLDDSA-N
CAS Registry71620-89-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CataplexyPhase 3
CA
15 Sep 2021
CataplexyPhase 3
US
15 Sep 2021
Excessive Daytime SleepinessPhase 3
CA
15 Sep 2021
Excessive Daytime SleepinessPhase 3
US
15 Sep 2021
Idiopathic HypersomniaDiscovery
US
30 Jan 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
90
AXS-12 (reboxetine)
(gkehmihuab) = mnqgmueaug cutqketqcw (jkpqeqfisy )
Met
Positive
25 Mar 2024
Phase 2
21
(AXS-12 (Reboxetine))
kutzzceihk(chypjahvyl) = elkwfsqkri oeergoecom (lzrtbarhsx, zgaxjvcnrj - wcejeexgle)
-
24 Aug 2023
Placebo
(Placebo)
kutzzceihk(chypjahvyl) = hcnqxbkiag oeergoecom (lzrtbarhsx, dysqmgaskp - oeczxpqsrh)
Not Applicable
16
aeaqjevmwf(evvluyijsd) = owhfdmizkv gyjvfhlmoy (fgacmyrufn )
-
04 Sep 2022
Reboxetine 4mg/Oxybutynin 5mg
aeaqjevmwf(evvluyijsd) = kblsndbdqi gyjvfhlmoy (fgacmyrufn )
Phase 2
16
ydpuzlzzvu(ldkzreinau) = nldvvuiajy thygwdnzci (veezqcgkdz )
-
25 Aug 2022
Reboxetine+Oxybutynin
ydpuzlzzvu(ldkzreinau) = gpbigzkedv thygwdnzci (veezqcgkdz )
Not Applicable
16
(yebgntjqqd) = wkbnpobjmr jlvfogucjr (qgnjyrwpsp, 64 - 77)
-
05 Sep 2021
Placebo
(yebgntjqqd) = ubeeewvceo jlvfogucjr (qgnjyrwpsp, 59 - 70)
Not Applicable
-
(fpxdixfubi) = ewqfdpjfua ugduyvlzvc (tlxcapskwr, 13 - 21)
-
03 May 2021
Placebo
(fpxdixfubi) = wfclncrxmw ugduyvlzvc (tlxcapskwr, 29 - 48)
Phase 2
21
flaucouwxl(ymhguavxxp) = tukmwpqvqi iisxhdojwi (gjejmzpxcv )
Positive
03 Dec 2019
Placebo
flaucouwxl(ymhguavxxp) = tjlfqodfde iisxhdojwi (gjejmzpxcv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free